These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33394961)

  • 41. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results.
    Mojana F; Cheng L; Bartsch DU; Silva GA; Kozak I; Nigam N; Freeman WR
    Am J Ophthalmol; 2008 Aug; 146(2):218-227. PubMed ID: 18538742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy.
    Eraslan S; Yıldırım Ö; Dursun Ö; Dinç E; Orekici Temel G
    Turk J Ophthalmol; 2020 Jun; 50(3):163-168. PubMed ID: 32631004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of Vitreoretinal Interface Abnormalities as Detected by Spectral-Domain Optical Coherence Tomography.
    Jacob J; Stalmans P
    Ophthalmologica; 2016; 236(2):81-7. PubMed ID: 27287013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors associated with spontaneous release of vitreomacular traction.
    Almeida DR; Chin EK; Rahim K; Folk JC; Russell SR
    Retina; 2015 Mar; 35(3):492-7. PubMed ID: 25207947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating the effect of vitreomacular interface abnormalities on anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema by optical coherence tomography: A systematic review and meta-analysis.
    Gong Y; Wang M; Li Q; Shao Y; Li X
    Photodiagnosis Photodyn Ther; 2023 Jun; 42():103555. PubMed ID: 37088331
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EPIRETINAL MEMBRANE IN EYES WITH VITREOMACULAR TRACTION.
    Carpineto P; Ciciarelli V; Borrelli E; Aharrh-Gnama A; Mastropasqua R
    Retina; 2019 Jun; 39(6):1061-1065. PubMed ID: 30964781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Higher Numbers of Hyperreflective Foci Seen in the Vitreous on Spectral-Domain Optical Coherence Tomographic Images in Eyes with More Severe Diabetic Retinopathy.
    Mizukami T; Hotta Y; Katai N
    Ophthalmologica; 2017; 238(1-2):74-80. PubMed ID: 28486219
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study.
    Paul C; Heun C; Müller HH; Hoerauf H; Feltgen N; Wachtlin J; Kaymak H; Mennel S; Koss MJ; Fauser S; Maier MM; Schumann RG; Mueller S; Chang P; Schmitz-Valckenberg S; Kazerounian S; Szurman P; Lommatzsch A; Bertelmann T
    Br J Ophthalmol; 2018 Aug; 102(8):1092-1097. PubMed ID: 29089354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progressive Release of Vitreomacular Traction With Aflibercept.
    Schwartz SG; Flynn HW
    Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):477-81. PubMed ID: 27183554
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
    Wong Y; Steel DHW; Habib MS; Stubbing-Moore A; Bajwa D; Avery PJ;
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):733-742. PubMed ID: 27957600
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Features of vitreomacular traction syndrome assessed with three-dimensional spectral-domain optical coherence tomography].
    Zhang ZQ; Dong FT; Yu WH; Dai RP; Zhao C; Yang ZK; Han BL; Du H
    Zhonghua Yan Ke Za Zhi; 2010 Feb; 46(2):106-12. PubMed ID: 20388342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
    Mikhail M; Stewart S; Seow F; Hogg R; Lois N
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anatomical and functional outcomes of pneumatic vitreolysis for treatment of vitreomacular traction with and without macular holes.
    Baumann C; Sabatino F; Zheng Y; Johannigmann-Malek N; Maier M; Kaye SB; Patton N
    Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2209-2215. PubMed ID: 35122133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.
    Steel DHW; Patton N; Stappler T; Karia N; Hoerauf H; Patel N; Wachtlin J; Raber T; Kozma-Wiebe P;
    Retina; 2021 Feb; 41(2):266-276. PubMed ID: 32496343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
    Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
    Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Size and vitreomacular attachment of primary full-thickness macular holes.
    Philippakis E; Amouyal F; Couturier A; Boulanger-Scemama E; Gaudric A; Tadayoni R
    Br J Ophthalmol; 2017 Jul; 101(7):951-954. PubMed ID: 27913441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ANATOMICAL AND FUNCTIONAL OUTCOMES OF SYMPTOMATIC IDIOPATHIC VITREOMACULAR TRACTION: A Natural History Study From the Pan American Collaborative Retina Study Group.
    Wu L; Zas M; Berrocal MH; Arevalo JF; Figueroa M; Rodriguez F; Serrano M; Graue F; Alezzandrini A; Gallego-Pinazo R; Roca JA; Iglicki M; Dalma-Weishauz J; Kozak I; Collado A; Badal J; Maia M; Salcedo-Villanueva G; Quiroz-Mercado H; Fromow-Guerra J; Lozano-Rechy D; Avila M; Chhablani J
    Retina; 2016 Oct; 36(10):1913-8. PubMed ID: 26966868
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
    Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
    Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.